Figure S9 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Sensitivity of LILRB2 as a predictive biomarker for pharmacodynamic response as measured by the macrophage polarization score in histoculture explant cultures.